Studies have demonstrated that ALA plasmatic concentrations are decreased in IPF patients [24] and that ALA alleviates BLM-induced mice lung fibrosis and angiotensin II (Ang II)-induced fibroblast activation by binding to the MrgD receptor [16, 19]. This evidence concerns the gene AGT and pulmonary fibrosis.